用于前列腺癌内放射治疗的177Lu标记放射性杂合PSMA配体的合成与临床前评价
本研究在LNCaP细胞和小鼠模型中系统比较了177Lu标记的放射性杂合PSMA配体(rhPSMA-7的4种异构体、rhPSMA-10.1和-10.2)与PSMA I&T及PSMA-617的亲和力、内化、亲脂性、白蛋白结合及生物分布。结果显示177Lu-Lu-rhPSMA-10.1在保持高肿瘤摄取的同时具有最低的肾脏摄取和最快的血池清除,作者认为高度有必要开展其临床研究。
要点
- 所有177Lu标记的rhPSMA配体均以低纳摩尔亲和力结合PSMA并具有高内化率。
- 177Lu-Lu-rhPSMA-7异构体表观分子量最高、白蛋白结合最强。
- 177Lu-Lu-rhPSMA-10.1肾脏摄取最低、血池清除最快且保持高肿瘤摄取。
核心结论
- 作者认为高度有必要对177Lu-Lu-rhPSMA-10.1开展临床研究,以确定在小鼠中观察到的有利药代动力学是否也能在患者中带来高肿瘤摄取和降低肾脏及其他非靶组织吸收剂量。
研究设计与样本
- 在LNCaP细胞上比较177Lu标记的rhPSMA-7的4种异构体(-7.1、-7.2、-7.3、-7.4)、新型放射性杂合配体rhPSMA-10.1和-10.2与PSMA I&T及PSMA-617的体外特性。
- 在LNCaP荷瘤小鼠注射后24小时进行生物分布研究和小动物SPECT显像。
- 体外评价包括半数抑制浓度亲和力研究、内化实验、亲脂性测量及表观分子量测定(作为人血清白蛋白结合参数)。
主要发现
- 所有配体均以低纳摩尔范围亲和力结合表达PSMA的LNCaP细胞,并具有高内化率。
- 177Lu-Lu-rhPSMA-7异构体表观分子量最高、人血清白蛋白相互作用最强;177Lu-Lu-rhPSMA-10.1的表观分子量低于177Lu-Lu-rhPSMA-7.3但高于177Lu标记的参照化合物PSMA I&T和PSMA-617。
- 在生物分布研究中,177Lu-Lu-rhPSMA-10.1在所有rhPSMA配体中肾脏摄取最低、血池清除最快,同时保持高肿瘤蓄积。
关键数值与推荐
- 177Lu标记按现有PSMA靶向配体的既定流程进行。
- 亲和力以半数抑制浓度表示,所有配体处于低纳摩尔范围(原文未给出具体数值)。
- 表观分子量排序为:177Lu-Lu-rhPSMA-7异构体最高,177Lu-Lu-rhPSMA-10.1低于177Lu-Lu-rhPSMA-7.3但高于PSMA I&T和PSMA-617(原文未给出具体数值)。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The prostate-specific membrane antigen (PSMA)-targeted radiohybrid (rh) ligand [177Lu]Lu-rhPSMA-7.3 has recently been assessed in a pretherapeutic dosimetry study on prostate cancer patients. In comparison to [177Lu]Lu-PSMA I&T, application of [177Lu]Lu-rhPSMA-7.3 resulted in a significantly improved tumor dose but also higher kidney accumulation. Although rhPSMA-7.3 has been initially selected as the lead compound for diagnostic application based on the characterization of its gallium complex, a systematic comparison of the most promising 177Lu-labeled rhPSMA ligands is still missing. Thus, this study aimed to identify the rhPSMA ligand with the most favorable pharmacokinetics for 177Lu-radioligand therapy. Methods: The 4 isomers of [177Lu]Lu-rhPSMA-7 (namely [177Lu]Lu-rhPSMA-7.1, -7.2, -7.3, and -7.4), along with the novel radiohybrid ligands [177Lu]Lu-rhPSMA-10.1 and -10.2, were compared with the state-of-the-art compounds [177Lu]Lu-PSMA I&T and [177Lu]Lu-PSMA-617. The comparative evaluation comprised affinity studies (half-maximal inhibitory concentration) and internalization experiments on LNCaP cells, as well as lipophilicity measurements. In addition, we determined the apparent molecular weight (AMW) of each tracer as a parameter for human serum albumin (HSA) binding. Biodistribution studies and small-animal SPECT imaging were performed on LNCaP-tumor bearing mice at 24 h after injection. Results: 177Lu labeling of the radiohybrids was performed according to the established procedures for the currently established PSMA-targeted ligands. All ligands showed potent binding to PSMA-expressing LNCaP cells, with affinities in the low nanomolar range and high internalization rates. Surprisingly, the most pronounced differences regarded the HSA-related AMW. Although [177Lu]Lu-rhPSMA-7 isomers demonstrated the highest AMW and thus strongest HSA interactions, [177Lu]Lu-rhPSMA-10.1 showed an AMW lower than for [177Lu]Lu-rhPSMA-7.3 but higher than for the 177Lu-labeled references PSMA I&T and PSMA-617. In biodistribution studies, [177Lu]Lu-rhPSMA-10.1 exhibited the lowest kidney uptake and fastest excretion from the blood pool of all rhPSMA ligands while preserving a high tumor accumulation. Conclusion: Clinical investigation of [177Lu]Lu-rhPSMA-10.1 is highly warranted to determine whether the favorable pharmacokinetics observed in mice will also result in high tumor uptake and decreased absorbed dose to kidneys and other nontarget tissues in patients.
引用
- Wurzer A, Kunert JP, Fischer S, et al. Synthesis and Preclinical Evaluation of 177Lu-Labeled Radiohybrid PSMA Ligands for Endoradiotherapy of Prostate Cancer. J Nucl Med. 2022. PMID: 35086894. doi:10.2967/jnumed.121.263371
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。